Table 2 Associations between the ESR1 and ESR2 genotype and prostatic cancer
Genotype | Control N = 352 (%) | Case N = 352 (%) | OR (95 % CI) |
|---|---|---|---|
rs2234693 ESR1 | |||
TT (Ref) | 80 (22.7 %) | 67 (19.0 %) | 1.00 |
CT | 175 (49.7 %) | 191 (54.3 %) | 1.08 (0.77–1.52) |
CC | 97 (27.6 %) | 94 (26.7 %) | 0.76 (0.49–1.18) |
CT + CC | 272 (77.3 %) | 285 (81.0 %) | 0.99 (0.71–1.36) |
rs1256049 ESR2 | |||
GG (Ref) | 167 (47.4 %) | 185 (52.6 %) | 1.00 |
AG | 146 (41.5 %) | 142 (40.3 %) | 0.88 (.64–1.20) |
AA | 39 (11.1 %) | 25 (7.1 %) | 0.58 (0.34–1.00)* |
AG + AA | 185 (52.6 %) | 167 (47.4 %) | 0.82 (0.61–1.10) |
rs4986938 ESR2 | |||
GG (Ref) | 254 (72.1 %) | 280 (79.5 %) | 1.00 |
AG | 90 (25.6 %) | 67 (19.1 %) | 0.68 (0.47–0.97)* |
AA | 8 (2.3 %) | 5 (1.4 %) | 0.57 (0.18–1.76) |
AG + AA | 98(27.9 % ) | 72 (20.5 %) | 0.67 (0.47–0.94)* |